Identity
Triptorelin is a synthetic GnRH agonist (also called an LHRH agonist) — a modified, longer-acting analog of the natural releasing hormone. It is sold as an approved medicine under names such as Decapeptyl, Trelstar and Diphereline, in depot forms designed for sustained release.
Mechanism (as proposed / established)
This is where triptorelin must be read carefully, because its effect runs opposite to intuition. As a sustained GnRH-receptor agonist, it first produces a brief flare — a surge in LH, FSH and sex hormones — and then, because the stimulation is continuous rather than pulsatile, it desensitises and downregulates the pituitary GnRH receptors. The downstream result is a shutdown of LH/FSH and therefore of testosterone or estrogen production: a reversible, medical "castration." This is the same pulsatile-versus-continuous principle seen with gonadorelin, taken to its therapeutic extreme — and it is precisely why triptorelin treats hormone-driven cancers.
The approved reality, and the dangerous inversion
Triptorelin's approved uses all rely on that suppression: advanced prostate cancer (removing the testosterone that fuels it), endometriosis and fibroids (lowering estrogen), and central precocious puberty (halting premature axis activation). The initial flare is clinically managed — in prostate cancer, with antiandrogen cover to prevent tumour flare.
The honest warning for this register: anyone meeting triptorelin as a "testosterone or fertility" research peptide has the mechanism backwards. It suppresses the axis; it does not boost it. It is a specialist prescription drug with real hypogonadal consequences — bone density, mood, sexual function — not a casual self-administered compound.